358 related articles for article (PubMed ID: 16281084)
1. Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism.
Wang Y; Shao C; Shi CH; Zhang L; Yue HH; Wang PF; Yang B; Zhang YT; Liu F; Qin WJ; Wang H; Shao GX
Asian J Androl; 2005 Dec; 7(4):375-80. PubMed ID: 16281084
[TBL] [Abstract][Full Text] [Related]
2. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy.
Xu XF; Zhou SW; Zhang X; Ye ZQ; Zhang JH; Ma X; Zheng T; Li HZ
Asian J Androl; 2006 Jul; 8(4):455-62. PubMed ID: 16763722
[TBL] [Abstract][Full Text] [Related]
3. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.
Fujinami K; Uemura H; Ishiguro H; Kubota Y
Int J Mol Med; 2002 Aug; 10(2):173-6. PubMed ID: 12119554
[TBL] [Abstract][Full Text] [Related]
4. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
5. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells.
Eder IE; Haag P; Basik M; Mousses S; Bektic J; Bartsch G; Klocker H
Mol Carcinog; 2003 Aug; 37(4):181-91. PubMed ID: 12891627
[TBL] [Abstract][Full Text] [Related]
6. Biphasic effect of androgens on prostate cancer cells and its correlation with androgen receptor coactivator dopa decarboxylase.
Shao C; Wang Y; Yue HH; Zhang YT; Shi CH; Liu F; Bao TY; Yang ZY; Yuan JL; Shao GX
J Androl; 2007; 28(6):804-12. PubMed ID: 17581945
[TBL] [Abstract][Full Text] [Related]
7. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
8. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
9. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
10. Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
Kim J; Park H; Im JY; Choi WS; Kim HS
Anticancer Res; 2007; 27(5A):3285-92. PubMed ID: 17970072
[TBL] [Abstract][Full Text] [Related]
11. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
12. Up-regulated expression of the MAT-8 gene in prostate cancer and its siRNA-mediated inhibition of expression induces a decrease in proliferation of human prostate carcinoma cells.
Grzmil M; Voigt S; Thelen P; Hemmerlein B; Helmke K; Burfeind P
Int J Oncol; 2004 Jan; 24(1):97-105. PubMed ID: 14654946
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor regulates Cdc6 in synchronized LNCaP cells progressing from G1 to S phase.
Bai VU; Cifuentes E; Menon M; Barrack ER; Reddy GP
J Cell Physiol; 2005 Aug; 204(2):381-7. PubMed ID: 15887248
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression.
Gao QZ; Lu JJ; Liu ZD; Zhang H; Wang SM; Xu H
Asian J Androl; 2008 Jul; 10(4):635-41. PubMed ID: 18097517
[TBL] [Abstract][Full Text] [Related]
15. GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
Rae JM; Johnson MD; Cordero KE; Scheys JO; Larios JM; Gottardis MM; Pienta KJ; Lippman ME
Prostate; 2006 Jun; 66(8):886-94. PubMed ID: 16496412
[TBL] [Abstract][Full Text] [Related]
16. Differentially expressed genes in androgen-dependent and -independent prostate carcinomas.
Chang GT; Blok LJ; Steenbeek M; Veldscholte J; van Weerden WM; van Steenbrugge GJ; Brinkmann AO
Cancer Res; 1997 Sep; 57(18):4075-81. PubMed ID: 9307296
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
[TBL] [Abstract][Full Text] [Related]
18. Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth.
Minamiguchi K; Kawada M; Ohba S; Takamoto K; Ishizuka M
Mol Cell Endocrinol; 2004 Feb; 214(1-2):175-87. PubMed ID: 15062556
[TBL] [Abstract][Full Text] [Related]
19. [Effect of dihydrotestosterone on the transcriptions and expressions of Smad3 and Smad4 in LNCaP cell line].
Gu RG; Zhou CW; Ma QZ
Zhonghua Nan Ke Xue; 2006 Mar; 12(3):211-4. PubMed ID: 16597033
[TBL] [Abstract][Full Text] [Related]
20. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
